When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?

To the Editor: I read with great interest the excellent narrative review by Badwan et al[1][1] regarding the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in acute heart failure. I thank the authors for their analysis of this complex and exciting topic. SGLT-2 inhibitors have been shown